In this article, we will take a look at the 10 Best Cheap AI Medicine Stocks to Buy Now.
Artificial intelligence is no longer limited to chatbots, digital advertising and Silicon Valley experiments. It is moving into hospitals, laboratories and pharmaceutical research, where algorithms are helping scientists discover potential medicines, interpret medical images, analyze genetic information and identify treatments suited to individual patients.
Interestingly, the termx term “artificial intelligence” was introduced in 1956, but medical AI took decades to become commercially practical. Modern healthcare systems now generate enormous amounts of clinical, imaging and genomic data—the exact type of information machine-learning models are designed to analyze.
Why Medicine Could Be AI’s Next Major Market
Drug development has traditionally required years of research, costly clinical trials and thousands of unsuccessful experiments. AI drug discovery platforms cannot eliminate those risks, but they can help researchers screen molecules, predict biological interactions and prioritize the most promising candidates before expensive trials begin.
Medical imaging has also become one of the earliest real-world applications of artificial intelligence in healthcare. AI-powered diagnostics can assist doctors in detecting abnormalities, improving image quality and prioritizing urgent cases. Meanwhile, precision medicine platforms are using clinical and genomic data to help match patients with more appropriate treatments.
These developments have encouraged investors to search for the best AI healthcare stocks, AI biotech stocks and medical AI companies positioned to benefit from the industry’s long-term expansion.
A Low Share Price Does Not Always Mean Cheap
A stock trading below $10 may look affordable, but it can still be overvalued if the company generates little revenue, loses money and repeatedly issues new shares. On the other hand, a profitable healthcare technology company trading above $50 may be undervalued when its earnings, cash flow and competitive advantages support a higher valuation.
The most attractive cheap AI medicine stocks therefore combine genuine medical applications with reasonable valuations, sufficient cash reserves, improving financial performance and meaningful long-term growth opportunities.
Finding the Best AI Medicine Stocks
This ranking evaluates NYSE- and Nasdaq-listed companies based on their AI exposure, valuation, revenue growth, financial strength, clinical potential and competitive position. Higher-risk companies were penalized for heavy losses, shareholder dilution, limited cash runways and uncertain paths to profitability.
The countdown begins with the most speculative AI medicine stock at No. 10 and ends with the strongest overall risk-adjusted pick at No. 1. These companies operate across AI drug discovery, precision medicine, genomic analysis, medical imaging, digital health and clinical research—some of the most promising fields where artificial intelligence could reshape modern healthcare.
CHECK THIS OUT: Top 10 Healthcare Stocks to Buy With $1000 in 2026 and 10 Best Medicine Stocks That Could Make Investors 100% Richer.
Our Methodology
For the 10 Cheap AI Medicine Stocks That Could Make You a Millionaire, we ranked each company based on its valuation, medical AI exposure, revenue growth, financial strength, clinical potential and overall investment risk.
10 Best Cheap AI Medicine Stocks to Buy Now
10. Lantern Pharma Inc. (NASDAQ:LTRN)
Lantern Pharma Inc. (NASDAQ: LTRN) begins the ranking as the smallest and most speculative AI medicine stock on the list. Trading at approximately $1.91 with a market capitalization of only around $24 million, the stock could produce enormous percentage gains if the company achieves a meaningful clinical breakthrough or secures a valuable pharmaceutical partnership. The opposite is equally possible: its limited financial resources could leave shareholders exposed to heavy dilution or permanent losses.
The company specializes in AI-powered precision oncology. Its RADR platform uses machine learning, biomarker information and multiomic data to identify which cancer patients may respond to particular treatments. Instead of discovering every medicine from zero, the company can also use artificial intelligence to search for additional applications for existing or previously studied drug candidates. This approach could theoretically reduce the cost and time required to bring cancer treatments into clinical development.
The pipeline includes programs targeting difficult cancers, including non-small cell lung cancer and glioblastoma. These diseases represent areas of considerable medical need, but success will ultimately depend on clinical evidence rather than the size of the company’s database or the sophistication of its algorithms.
The financial position makes the stock exceptionally risky. Cash, cash equivalents and marketable securities stood at approximately $7.4 million at the end of June 2026. The company also stated that it intends to pursue additional capital raises and collaborations to extend its operating runway. Its second-quarter operating loss improved by roughly 25% from a year earlier to approximately $3.5 million, but the available cash remains limited relative to ongoing research expenses. The figures were disclosed in the second-quarter financial report.
This is not a conventional cheap healthcare stock. It is a clinical-stage lottery ticket whose future could depend on financing, trial results and partnership announcements. Investors searching for high-risk AI biotech stocks may find the potential intriguing, but any position would need to remain small enough that a total loss would not cause serious portfolio damage.
